MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
152.50
+3.13
+2.10%
After Hours: 152.25 -0.25 -0.16% 19:56 02/06 EST
OPEN
149.69
PREV CLOSE
149.37
HIGH
153.13
LOW
148.71
VOLUME
8.51M
TURNOVER
--
52 WEEK HIGH
153.13
52 WEEK LOW
91.47
MARKET CAP
189.20B
P/E (TTM)
23.70
1D
5D
1M
3M
1Y
5Y
1D
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week
Seeking Alpha · 1h ago
Spotlight On Coca-Cola, Ford, AstraZeneca Earnings
Seeking Alpha · 2h ago
Gilead Sciences CEO Daniel O’Day Reports Disposal of Common Shares
Reuters · 20h ago
Catalyst Watch: Crypto swings, FedEx investor event, and Super Bowl bets
Seeking Alpha · 22h ago
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement?
NASDAQ · 1d ago
Noteworthy ETF Outflows: IYH, GILD, PFE, DHR
NASDAQ · 1d ago
Gilead wins favorable U.S. label update for Yescarta
Seeking Alpha · 1d ago
Invesco QQQ Trust ETF (QQQ) Daily Update, 2/6/2026
TipRanks · 1d ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.